Shares of Synlogic SYBX moved higher by 10.11% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 7.69% year over year to ($0.36), which beat the estimate of ($0.47).
Revenue of $0 decreased by 100.00% year over year, which missed the estimate of $280,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 05, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/5yiybtxn
Recent Stock Performance
Company's 52-week high was at $3.46
52-week low: $1.35
Price action over last quarter: down 2.79%
Company Profile
Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
